NPI | Name | Type | Address |
---|---|---|---|
PHARM.D. Robert J. Cersosimo |
Individual |
360 Huntington Ave 206 Mugar Boston, MA |
|
Kristina Mangan |
Individual |
88 East Newton St Boston, MA |
|
PHARM.D. Radhika Sane |
Individual |
88 E Newton St Boston, MA |
|
DR. PHARMD James Bennett |
Individual |
300 Longwood Ave Boston, MA |
|
PHARMD Mark Leonard Zangardi |
Individual |
55 Fruit St Grb005 Boston, MA |
|
PHARMD Ewha Bridget Kim |
Individual |
55 Fruit St Yawkey Bldg 8th Floor, Massachusetts General Hospital Boston, MA |
|
DR. PHARM.D Leila Rostamnjad |
Individual |
50 Fruit St Boston, MA |
|
DR. PHARMD, BCOP Bridget C Scullion |
Individual |
450 Brookline Ave Dept Of Boston, MA |
|
PHARMD Houry Leblebjian |
Individual |
450 Brookline Ave Boston, MA |
|
Tsz-yi Wendy Chen |
Individual |
450 Brookline Ave Boston, MA |
|
PHARMD, BCOP Jameson B Wood |
Individual |
150 S Huntington Ave Boston, MA |
|
David Hughes |
Individual |
830 Harrison Ave Fl 3 Boston, MA |
|
PHARMD Jasmine Patel |
Individual |
830 Harrison Ave Bldg 3 Boston, MA |
|
PHARMD, BCOP Alison Stebbings |
Individual |
830 Harrison Ave Boston, MA |
|
PHARMD Lynnette Henshaw |
Individual |
850 Harrison Ave Boston, MA |
|
PHARMD Adrian Zobniw |
Individual |
830 Harrison Ave Boston, MA |
|
DR. PHARMD Simon Gorelikov |
Individual |
830 Harrison Ave Fl Center3 Boston, MA |
|
PHARMD Kimberly Tsou |
Individual |
830 Harrison Ave Boston, MA |
|
PHARMD, BCOP Stefanie Clark |
Individual |
133 Brookline Ave Boston, MA |
|
DR. PHARMD Marina Kaymakcalan |
Individual |
450 Brookline Ave Boston, MA |
Every health care provider, whether it’s a hospital, pharmacy, or individual specialist, must obtain their own NPI number. This identification number is unique and is assigned upon application. In tod...
Taxonomy Code | 1835X0200X |
Specialization | Oncology |
Display Name | Oncology Pharmacist |
Taxonomy Group | Pharmacy Service Providers |
Taxonomy Classification | Pharmacist |
Definition | A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases. |
Effective Date | September 30, 2009 |